Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma

Exclusion Criteria

• •Prior chemotherapy or radiation therapy for NSCLC
• •Prior treatment with bevacizumab or other agents specifically targeting vascular endothelial growth factor (VEGF)
• •Patients with known hypersensitivity to other recombinant human antibodies
• •History of stroke or transient ischemic attack (TIA).
• •History of myocardial infarction or unstable angina within the past 12 months.
• •Other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), symptomatic diverticulitis, or active uncontrolled infection.
• •Women who are pregnant or breast-feeding